Klotho announces 18 claims within patent application in Australia for s-KL

Klotho Neurosciences (KLTO)announces the acceptance of 18 claims within a patent application filed in Australia for composition and use of human secreted Klotho protein, or s-KL, isoform of the human gene sequence. The Australian government entity IP Australia has notified the Company and the licensor of the technology, Universitat Autonoma de Barcelona, that these claims are to be granted. The 18 claims cover the use of a human muscle-cell specific promoter operatively linked to a nucleic acid gene sequence encoding human the human s-KL protein for treating motor impairment. The claims also cover the use of neuronal cells and induced pluripotent stem cells, or iPSC, containing the muscle-cell specific promoter and s-KL nucleic acid gene sequence encoding human the human s-KL protein and other cellular delivery systems such as adeno-associated viral vectors, or non-viral vectors with muscle-cell and/or motor neuron-cell tropism.